

COPY OF ERS
ORIGINALLY FILED

3721

PATENT RECEIVED
MAR 19 2002
MAIL ROOM
L. Nelson
#2/IDS
3/28/02

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE
UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS
MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER OF PATENTS,
WASHINGTON, D.C. 20231, ON MARCH 5, 2002.

SUSAN C. SHEZHAN

Attorney Docket No. DEL-059 PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Murari et al.

Serial No.: 09/925,348

Filed: August 9, 2001

For: Improved Solid Pharmaceutical

Dosage Formulation of Hydrophobic Drugs

Group Art Unit No.: 3721

Examiner: unknown

Commissioner of Patents

Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.56**

Applicants herein make available to the Patent and Trademark Office copies of the references, listed on the included Form PTO-1449.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

(1) **This Information Disclosure Statement is being filed:**

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.
- ☒ **before** the mailing date of a first Office Action on the merits.
- ☐ **after** the mailing date of the first Office Action on the merits, but **before** the mailing date of
 - a Final Action under 37 CFR 1.113,
 - a Notice of Allowance under 37 CFR 1.311, or
 - an action that otherwise closes prosecution,and is accompanied by either:
 - ☒ the Statement under 37 CFR 1.97(e) (see "Statement" below), or
 - ☐ the fee under 37 CFR 1.17(p).
- ☐ **after** the mailing date of
 - a Final Action under 37 CFR 1.113,
 - a Notice of Allowance under 37 CFR 1.311, or
 - an action that otherwise closes prosecution,,and is accompanied by both:
 - the Statement under 37 CFR 1.97(e) (see "Statement" below), and
 - the fee under 37 CFR 1.17(p).

(2) **Statement**

- ☒ The **undersigned attorney** hereby states that each item information contained in the Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

(If this box is checked, do not check any further Statement boxes.)

or

- ☐ The **person signing immediately below** hereby states that no item of information contained in the Supplemental Information Disclosure was cited in any communication from any foreign patent office in any counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual

Serial No. C9/925,348
Group Art Unit: 3721

designated in 37 CFR 1.56(c) more than three months prior to the filing of the Supplemental Information Disclosure Statement.

The person making the statement is:

☐ the inventor(s) who sign(s) below:

Signature of the Inventor(s)

Typed or Printed Name of the Inventor(s)

or

☐ a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below:

Signature of the Person(s)

Typed or Printed Name of the Person

Address of Person Signing

or

☐ the undersigned attorney who signs on the basis of the information:

- ☐ supplied by the inventor(s).
- ☐ supplied by an individual designated in 37 CFR 1.56(c).
- ☐ in the attorney's file.

Signature of the Attorney

Serial No. 09/925,348
Group Art Unit: 3721

(4) **Fees**

- ☒ **No Fee** is owed by the applicants.
- ☐ **The IDS Fee** of \$_____ under 37 CFR 1.17(p) is enclosed herewith.

(5) **Method of Payment of Fees**


- ☐ Attached is a check in the amount of \$_____.
- ☐ Applicants hereby authorize the Commissioner to charge the \$_____ IDS Fee to Deposit Account No. 04-0480.

(6) **Authorization to Charge Additional Fees**

- ☒ Applicants hereby authorize the Commissioner to charge any additional fees deemed required for consideration of this Paper to Deposit Account No. 04-0480.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,


Arthur E. Jackson
Registration No. 34,354
Attorney for Applicant

DECHERT
4000 Bell Atlantic Tower
1717 Arch Street
Philadelphia, PA 19103-2793

Arthur E. Jackson, Esq.
(609) 620-3254